Immunocore Ltd
Clinical trials sponsored by Immunocore Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New targeted therapy shows promise for Hard-to-Treat cancers Results expected Oct 2026 (estimated)
- New bispecific drug targets Hard-to-Treat cancers in early trial Results expected Nov 2026 (estimated)
-
New combo therapy aims to boost melanoma treatment
Disease control Recruiting nowThis study tests whether adding an experimental drug (IMC-F106C) to standard immunotherapy (nivolumab) works better than standard treatment alone for people with advanced melanoma. About 680 adults with a specific genetic marker (HLA-A*02:01) and previously untreated advanced mel…
Phase 3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New immune drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called IMC-P115C in people with advanced cancers that have a specific protein (PRAME) and a certain immune type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The study will check safety and whet…
Phase 1 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to extend life in advanced melanoma
Disease control Recruiting nowThis study tests a new drug, tebentafusp, alone or with pembrolizumab, in people with a specific genetic type (HLA-A*02:01) of advanced melanoma that has been treated before. The main goal is to see if these treatments help people live longer compared to other available options. …
Phase 3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New bispecific drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMC-R117C, alone or with other cancer drugs, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific genetic marker (HLA-A*02:01) and produce a protein called PIWIL1. The trial aims to find safe doses and…
Phase 1/2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC